Pages that link to "Q80236890"

The following pages link to Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis (Q80236890):

Displaying 19 items.

• Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients (Q33308506) (← links)
• Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α. (Q35028578) (← links)
• Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease (Q35602513) (← links)
• Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease (Q36796750) (← links)
• Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner (Q37331280) (← links)
• Evaluation of Beneficial Metabolic Effects of Berries in High-Fat Fed C57BL/6J Mice. (Q37616144) (← links)
• Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease (Q39679120) (← links)
• Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease (Q40618944) (← links)
• Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis (Q42000430) (← links)
• The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk (Q43230115) (← links)
• Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (Q44732903) (← links)
• Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial (Q46216843) (← links)
• Prothrombotic factors and nonalcoholic fatty liver disease: an additional link to cardiovascular risk? (Q46630941) (← links)
• Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice. (Q64943406) (← links)
• NASH predicts plasma inflammatory biomarkers independently of visceral fat in men (Q80964439) (← links)
• NAFLD Recurrence in Liver Transplant Recipients (Q83240524) (← links)
• Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA (Q89851343) (← links)
• Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation (Q92965575) (← links)
• Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis (Q100994723) (← links)